Zobrazeno 1 - 10
of 68
pro vyhledávání: '"Angela M Crook"'
Autor:
Charles S Morrison, Pai-Lien Chen, Cynthia Kwok, Jared M Baeten, Joelle Brown, Angela M Crook, Lut Van Damme, Sinead Delany-Moretlwe, Suzanna C Francis, Barbara A Friedland, Richard J Hayes, Renee Heffron, Saidi Kapiga, Quarraisha Abdool Karim, Stephanie Karpoff, Rupert Kaul, R Scott McClelland, Sheena McCormack, Nuala McGrath, Landon Myer, Helen Rees, Ariane van der Straten, Deborah Watson-Jones, Janneke H H M van de Wijgert, Randy Stalter, Nicola Low
Publikováno v:
PLoS Medicine, Vol 12, Iss 1, p e1001778 (2015)
BackgroundObservational studies of a putative association between hormonal contraception (HC) and HIV acquisition have produced conflicting results. We conducted an individual participant data (IPD) meta-analysis of studies from sub-Saharan Africa to
Externí odkaz:
https://doaj.org/article/c1b0c8811a234180b6770381629ca374
Autor:
James M Mason, Kim S Thomas, Angela M Crook, Katharine A Foster, Joanne R Chalmers, Andrew J Nunn, Hywel C Williams
Publikováno v:
PLoS ONE, Vol 9, Iss 2, p e82694 (2014)
BackgroundCellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. We assessed the cost-effectiveness of prophylactic antibiotic treatment to prevent the recurrence of cellulitis using low dose pe
Externí odkaz:
https://doaj.org/article/61adb22c1ff34c5e9f4a4c82dbb91fbd
Autor:
Conor D. Tweed, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Lerato Mohapi, Michael E. Murphy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman, Stephen H. Gillespie
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count > 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure rates according to H
Externí odkaz:
https://doaj.org/article/d4f6503cd6b943dbb18e73105c9b0eb8
Autor:
Nicholas I. Paton, Christopher Cousins, Celina Suresh, Erlina Burhan, Ka Lip Chew, Victoria B. Dalay, Qingshu Lu, Tutik Kusmiati, Vincent M. Balanag, Shu Ling Lee, Rovina Ruslami, Yogesh Pokharkar, Irawaty Djaharuddin, Jani J.R. Sugiri, Rholine S. Veto, Christine Sekaggya-Wiltshire, Anchalee Avihingsanon, Rohit Sarin, Padmasayee Papineni, Andrew J. Nunn, Angela M. Crook
Publikováno v:
New England Journal of Medicine. 388:873-887
Autor:
Nurulamin M. Noor, Sarah L. Pett, Hanif Esmail, Angela M. Crook, Claire L. Vale, Matthew R. Sydes, Mahesh K.B. Parmar
Publikováno v:
F1000Research, Vol 9 (2020)
Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations. Early work focused on rapid sequencing of severe acute respir
Externí odkaz:
https://doaj.org/article/61d8b86fa4a24a4f819a91086761b336
Autor:
Anna Turkova, Genevieve H. Wills, Eric Wobudeya, Chishala Chabala, Megan Palmer, Aarti Kinikar, Syed Hissar, Louise Choo, Philippa Musoke, Veronica Mulenga, Vidya Mave, Bency Joseph, Kristen LeBeau, Margaret J. Thomason, Robert B. Mboizi, Monica Kapasa, Marieke M. van der Zalm, Priyanka Raichur, Perumal K. Bhavani, Helen McIlleron, Anne-Marie Demers, Rob Aarnoutse, James Love-Koh, James A. Seddon, Steven B. Welch, Stephen M. Graham, Anneke C. Hesseling, Diana M. Gibb, Angela M. Crook
Publikováno v:
The New England Journal of Medicine, 386, 911-922
The New England Journal of Medicine, 386, 10, pp. 911-922
The New England Journal of Medicine, 386, 10, pp. 911-922
Contains fulltext : 249121.pdf (Publisher’s version ) (Open Access) BACKGROUND: Two thirds of children with tuberculosis have nonsevere disease, which may be treatable with a shorter regimen than the current 6-month regimen. METHODS: We conducted a
Autor:
Tra My Pham, Conor D Tweed, James R Carpenter, Brennan C Kahan, Andrew J Nunn, Angela M Crook, Hanif Esmail, Ruth Goodall, Patrick PJ Phillips, Ian R White
Publikováno v:
Clinical trials (London, England), vol 19, iss 5
Background/aims Tuberculosis remains one of the leading causes of death from an infectious disease globally. Both choices of outcome definitions and approaches to handling events happening post-randomisation can change the treatment effect being esti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::338740b80454e2daf8bf48a2ae21b87c
https://escholarship.org/uc/item/0p81432n
https://escholarship.org/uc/item/0p81432n
Autor:
Francesca, Conradie, Tatevik R, Bagdasaryan, Sergey, Borisov, Pauline, Howell, Lali, Mikiashvili, Nosipho, Ngubane, Anastasia, Samoilova, Sergey, Skornykova, Elena, Tudor, Ebrahim, Variava, Petr, Yablonskiy, Daniel, Everitt, Genevieve H, Wills, Eugene, Sun, Morounfolu, Olugbosi, Erica, Egizi, Mengchun, Li, Alda, Holsta, Juliano, Timm, Anna, Bateson, Angela M, Crook, Stella M, Fabiane, Robert, Hunt, Timothy D, McHugh, Conor D, Tweed, Salah, Foraida, Carl M, Mendel, Melvin, Spigelman, Adam A, Witney
Background\ud The bedaquiline–pretomanid–linezolid regimen has been reported to have 90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events with 1200 mg of linezolid daily has been high. The appropriate dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e75b3743b92e3e20f2adaedefafd0c1
https://openaccess.sgul.ac.uk/id/eprint/114768/1/NEJMoa2119430.pdf
https://openaccess.sgul.ac.uk/id/eprint/114768/1/NEJMoa2119430.pdf
Pretomanid with bedaquiline and linezolid for drug-resistant TB: a comparison of prospective cohorts
Autor:
Francesca Conradie, G Wills, M. Olugbosi, A Calatroni, Mendel Carl M, Pauline Howell, Daniel Everitt, E Sun, N Ngubane, Aliasgar Esmail, A. del Parigi, Angela M. Crook, Melvin Spigelman, Andreas H. Diacon, Olatunde Olayanju, Keertan Dheda, Suzette Oelofse
Publikováno v:
The International Journal of Tuberculosis and Lung Disease. 25:453-460
BACKGROUND: There are no data comparing the 6–9 month oral three-drug Nix regimen (bedaquiline, pretomanid and linezolid [BPaL]) to conventional regimens containing bedaquiline (B, BDQ) and linezolid (L, LZD).METHODS: Six-month post end-of-treatmen
Autor:
Francesca, Conradie, Andreas H, Diacon, Nosipho, Ngubane, Pauline, Howell, Daniel, Everitt, Angela M, Crook, Carl M, Mendel, Erica, Egizi, Joanna, Moreira, Juliano, Timm, Timothy D, McHugh, Genevieve H, Wills, Anna, Bateson, Robert, Hunt, Christo, Van Niekerk, Mengchun, Li, Morounfolu, Olugbosi, Melvin, Spigelman, Priya, Solanki
Publikováno v:
The New England Journal of Medicine
Patients with highly drug-resistant forms of tuberculosis have limited treatment options and historically have had poor outcomes.In an open-label, single-group study in which follow-up is ongoing at three South African sites, we investigated treatmen